



## Conatus Pharmaceuticals to Participate in H.C. Wainwright Global Life Sciences Conference

April 2, 2019

SAN DIEGO, April 02, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) has accepted an invitation to participate in the H.C. Wainwright Global Life Sciences Conference (April 7-9 in London). Conatus senior management will conduct a series of scheduled meetings with investment professionals and present a company overview on Tuesday, April 9, 2019, from 10:30 a.m. to 10:50 a.m. BST (5:30 a.m. to 5:50 a.m. EDT). A webcast of the presentation will be available live and archived in the Investors section of the Conatus website at [www.conatuspharma.com](http://www.conatuspharma.com).

### About Conatus Pharmaceuticals

Conatus is a biotechnology company focused on the development and commercialization of novel medicines to treat chronic diseases with significant unmet need. In collaboration with Novartis, Conatus is developing its lead in-licensed compound, emricasan, for the treatment of patients with NASH-driven chronic liver diseases. Conatus is independently developing its lead internally developed compound, CTS-2090, for the treatment of patients with chronic diseases involving inflammasome pathways. For additional information, please visit [www.conatuspharma.com](http://www.conatuspharma.com).

### Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including those risks described in the company's prior press releases and in the periodic reports it files with the Securities and Exchange Commission. The events and circumstances reflected in the company's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, the company does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

**CONTACT:** Alan Engbring  
Conatus Pharmaceuticals Inc.  
(858) 376-2637  
[aengbring@conatuspharma.com](mailto:aengbring@conatuspharma.com)



Source: Conatus Pharmaceuticals Inc.